New Two-Pronged immune cell attack tested for tough leukemias
NCT ID NCT04049383
Summary
This early-phase study tested the safety of a new type of CAR-T cell therapy designed to fight B-cell acute lymphoblastic leukemia (ALL) that has come back or not responded to other treatments. The therapy involved taking a patient's own immune cells, modifying them in a lab to recognize two targets (CD19 and CD20) on leukemia cells, and then infusing them back into the patient. The main goal was to find a safe dose and see how patients tolerated the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.